Adimab, LLC 4
4 · Adagio Therapeutics, Inc. · Filed Aug 12, 2021
Insider Transaction Report
Form 4
Adimab, LLC
10% Owner
Transactions
- Conversion
Common Stock
2021-08-10+25,860,700→ 27,845,995 total - Conversion
Series A Preferred Stock
2021-08-10−5,000,000→ 0 total→ Common Stock (25,000,000 underlying) - Conversion
Series C Preferred Stock
2021-08-10−128,064→ 0 total→ Common Stock (640,320 underlying) - Conversion
Series B Preferred Stock
2021-08-10−44,076→ 0 total→ Common Stock (220,380 underlying)
Footnotes (1)
- [F1]Each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock automatically converted, without payment of additional consideration, into Common Stock on a 5:1 basis immediately prior to the closing of the Issuer's initial public offering of its Common Stock and had no expiration date.